Shared decision making in mental health: prospects for personalized medicine by Drake, Robert E. et al.
he current complexity of treatments and out-
comes in modern medicine presents a fundamental
dilemma. Few medical treatment decisions involve a clear
best choice; the typical medical decision involves trade-
offs among multiple partially effective interventions with
different risks. Consider the case of surgical interventions.
Placing a pin in a fractured hip represents a rare case of
a consensual best treatment for almost every patient. In
many other common surgical situations, the evidence is
considerably more complicated. For example, surgery for
benign prostatic hypertrophy produces better urine flow
at the risk of incontinence and impotence. When men
understand the tradeoffs accurately, many prefer med-
ications or watchful waiting.
1 Similarly, for early breast
cancer, spinal disk injury, prostate cancer, rotator cuff
injuries, uterine fibroids, coronary artery disease, and
many other surgical conditions, choice among different
interventions with complex outcomes and adverse effects
is the rule.
2This fundamental dilemma gives rise to the
belief that patients should be involved in making medical
decisions generally, and to the paradigm of shared deci-
sion making more specifically.
Shared decision making assumes that two experts (or
teams of experts) should collaborate in making complex
medical decisions.
3The health care provider (often a team
of professionals) brings expertise in understanding the
medical problem, the possible interventions, and the
potential benefits and risks of alternatives. The patient
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This paper describes the shared decision-making model,
reviews its current status in the mental health field, and
discusses its potential impact on personalized medicine.
Shared decision making denotes a structured process
that encourages full participation by patient and
provider. Current research shows that shared decision
making can improve the participation of mental health
patients and the quality of decisions in terms of knowl-
edge and values. The impact of shared decision making
on adherence, illness self-management, and health out-
comes remains to be studied. Implementing shared deci-
sion making broadly will require re-engineering the flow
of clinical care in routine practice settings and much
greater use of information technology. Similar changes
will be needed to combine genomic and other biologi-
cal data with patients’ values and preferences and with
clinicians’ expertise. The future of personalized medicine
is clearly linked with our ability to create the infrastruc-
ture and cultural receptivity to these changes.  
© 2009, LLS SAS Dialogues Clin Neurosci. 2009;11:455-463.
455 Copyright © 2009 LLS SAS.  All rights reserved www.dialogues-cns.org
DCNS_43_4.qxd:DCNS#43  1/12/09  23:59  Page 455(often assisted by family or support network members)
brings expertise related to understanding the individual’s
values, goals, supports, and preferences. Shared decision
making generally involves both partners presenting their
respective views and then negotiating a plan that both
agree is ethical, consistent with the evidence, congruent
with the patient’s preferences, and practical. Conceptually,
shared decision making falls between two extreme
approaches to medical decision making: the paternalis-
tic and the autonomous decision models.
4 In the tradi-
tional, paternalistic model, the physician assesses what is
best for a particular patient, based on scientific evidence
and clinical judgment, and makes the decision. In the
autonomous decision model, the patient is presented with
information, weighs the information, and makes the
choice unilaterally.
As a simple example of shared decision making, con-
sider a young woman who suddenly develops radiating
pain as a result of a back injury. Her medical exam and
magnetic resonance imaging reveal a lumbar disk pro-
trusion. Her physician describes alternative approaches
that include surgery, nerve blocks, a back brace, physical
therapy, and watchful waiting. The patient and her par-
ents are averse to surgery, especially when they under-
stand the risks, and prefer conservative treatment. The
physician agrees that wearing a brace and waiting for 2
months to re-evaluate the injury is reasonable. Two
months later, she is much improved, and they agree that
exercise is the best strategy.
Now consider a more complex decision. A second young
woman develops a breast lump and is diagnosed with
uncomplicated early breast cancer. Her physician reviews
with her the surgical alternatives (lumpectomy vs breast
removal) as well as adjunctive chemotherapy and radi-
ation therapy, and describes the risks and benefits of
each. Due to the early stage of illness, the physician
clearly believes that the patient is an excellent candidate
for lumpectomy. Because of a strong family history and
the experience of watching her mother die of breast can-
cer, however, the young woman prefers bilateral mas-
tectomy. After further discussion with the patient and her
husband, the physician understands and accepts the
patient’s decision and performs the more radical surgery.
In this case, the physician initially disagrees with the
patient’s choice but accepts the patient’s preference and
right to make the decision.
The medical literature and research evidence on shared
decision making, decision supports, and decision aids are
extensive and growing rapidly.
5 For example, there are
now literally hundreds of decision aids to help patients
make medical decisions. The diversity of these instru-
ments has led recently to the development of interna-
tional standards.
6The evidence shows that decision aids
help patients to make more informed decisions that are
more congruent with their values and preferences.
7
Longer-term effects on basic health outcomes are not yet
well studied. 
Shared decision making in 
mental health: current status
Several arguments suggest the importance of shared
decision making in mental health. First and foremost,
effective mental health care should be person-centered.
8,9
As is true with other long-term illnesses,
10,11 empowering
people to be knowledgeable and active in managing their
own mental illnesses is critical.
12 Decisions related to
chronic illnesses differ from acute-care decisions in sev-
eral ways: for example, there are many opportunities to
make and revisit the decisions, and the patient must take
much greater responsibility in carrying out decisions
daily.
10 Because of personal values and subjective
responses, patients themselves can best evaluate trade-
offs in efficacy and side effects.
13,14 In mental health,
shared decision making enhances the working relation-
ship needed to optimize long-term outcomes.
15 For exam-
ple, learning to manage one’s illness with medications
involves a dynamic, longitudinal process that encom-
passes resolving decisional conflicts, conducting experi-
ments, balancing positive and negative effects, and mak-
ing changes. A close working alliance between
practitioner and client is the sine qua non of success.
In addition to these practical concerns, others have made
ethical and legal arguments for shared decision making.
Autonomy—the right to make decisions regarding one’s
body—has long been a fundamental principle of Western
medical ethics.
16 Recognizing the importance of auton-
omy, the legal standard for medical care is shifting from
informed consent to informed choice among reasonable
alternatives.
17 
Most mental health patients express a desire to partici-
pate in making decisions regarding medications and hos-
pitalizations.
18-21 Nevertheless, shared decision making is
not prominent in widely disseminated psychiatric med-
ication algorithms
22 and not usually practiced in daily
medication management.
15 Patients with severe and per-
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making medical decisions is usually passive.
18,21,23 Further,
many psychiatrists consistently report that shared deci-
sion making is not applicable to decisions regarding med-
ications and hospitalizations due to patients’ decisional
incapacity.
24,25
At the same time, the evidence in support of shared deci-
sion making in mental health is expanding rapidly. First,
nearly all psychiatric patients, even the great majority of
those with the most severe disorders such as schizophre-
nia, are capable of understanding treatment choices and
making rational decisions.
26-28 Like many other patients
with limited education, learning disorders, or other dis-
advantages, some require repetition of information or
multimodal sources of information.
29Also, some psychi-
atric patients experience temporary decisional incapac-
ity, such as during psychotic episodes, and may elect to
establish psychiatric advanced directives to cover such
periods of decisional incapacity.
30
Second, shared decision making constitutes a core prin-
ciple of many effective mental health practices and may,
in part, explain their effectiveness.
12,31-33 For example, hon-
oring the client’s preference for type of job is a funda-
mental principle of supported employment, and the
entire model follows the client’s decisions about when to
search for a job, how many hours to work, whether or not
to disclose illness to the potential employer, supports on
the job, manner of follow-up, and so on.
34 Emphasis on
shared decision making is also built into illness manage-
ment and recovery,
12 behavioral family therapy,
35 inte-
grated dual disorders treatment,
36 and systematic med-
ication management.
37Assertive community treatment,
which was historically criticized for paternalism, is also
becoming more client-centered.
38
Third, although research on shared decision making in
mental health is in its infancy, seven initial randomized
controlled trials support its effectiveness. Malm et al
39
provided multiple shared decision-making sessions within
a treatment program for schizophrenia patients, and
found that the experimental group had higher ratings of
patient satisfaction than controls at 2 years. Van Korff et
al
40 provided multiple sessions of shared decision making
to depressed patients, and found better adherence and
depression symptom outcomes favoring experimental
over control participants at 3, 6, 9, and 12 months. Van Os
et al gave one session of shared decision making to
patients with schizophrenia and their doctors in a ran-
domized clinical trial and found that the experimental
patients reported improvements in quality of patient-
doctor communication and that the intervention induced
changes in medication management immediately.
41
Hamann et al
42 conducted a randomized controlled trial
with schizophrenia inpatients and found increased
knowledge and perceived involvement in decisions by
the experimental group during hospitalization. Priebe et
al
43 used a cluster randomized design to study use of a
computer-mediated intervention to structure patient-clin-
ician interactions regarding quality of life and needs for
care every 2 months for a year. Schizophrenia patients in
the experimental group had better subjective quality of
life, fewer unmet needs, and greater satisfaction with
treatment at 1 year. Loh et al
44 used a cluster randomized
design to study a shared decision-making intervention
with depressed patients. At 6- to 8-week follow-up, exper-
imental group patients reported greater participation in
decision making and greater satisfaction with care,
although the intervention did not impact severity of
depressive symptoms. Joosten et al
45 used a cluster ran-
domized design to study shared decision making within
inpatient addiction treatment programs. Patients who
received shared decision making rather than traditional
decision making had greater reductions in drug use and
psychiatric symptoms at 3-month follow-up. Woltmann
46
used a cluster randomized design to study shared deci-
sion making during one session of treatment planning
between case managers and clients with severe and per-
sistent mental illnesses. Clients and case managers in the
shared decision-making group were more likely to report
that decisions were collaborative. 
Thus, as in general medicine, the initial research in men-
tal health shows that shared decision making increases
the quality of decisions (knowledge, participation, and
congruence with values), but there is minimal evidence
regarding objective health outcomes. Long-term studies
of health outcomes related to greater knowledge, partic-
ipation in illness self-management, and better relation-
ships with practitioners need to be evaluated. 
The doctor’s role in shared decision making
In this section, we illustrate some of the barriers to imple-
menting shared decision making in mental health by
examining the outpatient psychiatrist’s role. The central
point is that practising shared decision making involves
much more than endorsing the concept. The complex
structure and process of care must support the desired
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patients need significant time,
4 facilitated communica-
tion,
47 and easy access to clinically useful current scientific
knowledge.
48 These conditions do not currently exist in
psychiatric office practice in the US. Therefore, the
process of care will need to be redesigned to make shared
decision making the easy and natural way to practice.
49
Psychiatric office visits are complex and dynamic inter-
actions that are packed with psychological, interpersonal,
and practical tasks. These include establishing a trusting
relationship; identifying goals for the encounter; gather-
ing needed information, such as assessing and addressing
symptoms, function, and/or side effects of treatment;
planning the next steps; documenting the encounter; pre-
scribing medications; communicating with other
providers; and filling out forms.
50 The time for shared
decision making must come from time usually spent on
these other tasks because expanding visit length is cur-
rently prohibited by costs.
Addressing the time dilemma will require re-engineering
office practice and using information technology.
51At the
microsystem level, a trained and organized team (an acti-
vated patient, support from other staff, and a well-designed
information system) can create efficiencies in the flow of
the office visit.
52Team members other than the psychiatrist
can elicit and record the patients’ current concerns, expe-
riences, and values.
53They can also obtain required vital
signs, track down lab values, fill out sections of forms the
psychiatrist needs to sign, prepare prescriptions for physi-
cian review and signature, and help the patient to be as
active as possible, including direct participation in collect-
ing information through patient portals to the electronic
medical record. A well-designed electronic medical record
can increase efficiency (and improve care) by collecting
and graphically displaying patient-entered information,
laying out evidenced-based treatment algorithms, and
streamlining common required tasks such as clinical doc-
umentation, prescription writing, and clinical communica-
tion to other health care providers.
54
Many people, including both those with and without psy-
chiatric symptoms, find it difficult to express themselves
in doctors’ offices. The medical care process is not trans-
parent, and people do not naturally know what informa-
tion is relevant and important to communicate. Further,
medical settings are often intimidating, and people are
nervous. Nevertheless, the voice of the patient must be at
the heart of the decision-making process. Without hear-
ing the patient’s chief current concerns, subjective life
experiences, and core values, decisions lack both data and
salience to the patient’s life.
55
Currently, all information about the patient’s perspective
comes from the dialog between the psychiatrist and the
patient during the busy office visit. Important issues, such
as whether the patient’s chief concerns for the session are
routinely elicited and whether the patient experience is
gathered in a valid, reliable manner, are up to self-
designed practice habits of the psychiatrist.
55Without a
system designed to elicit, organize, and amplify the voice
of the patient, the psychiatrist can easily miss information
that would make the clinical decisions much more
informed, relevant, and collaborative.
Re-engineering the office could facilitate communication
in three ways. First, the redesign could increase the con-
fidence and ability of patients to be active participants in
the care process by explicitly welcoming them when they
arrive for service, orienting them to the care process, and
providing accessible education on the illnesses and the
treatment options. Second, the patient’s voice could be
amplified by explicitly eliciting and documenting chief
concerns, experiences, and core values. If this inquiry
occurs before the actual encounter, the information is
more likely to be complete, the patient’s questions will
be written down so they are not forgotten, and the visit
time is freed up for double-checking understanding and
for in-depth discussion. Finally, symptoms, medication
side effects, and functional status questions can be asked
in a systematic fashion using standardized instruments by
computer,
55,57,58 and the longitudinal results can be dis-
played graphically. Computerization allows the patient
and the psychiatrist to examine progress and base dis-
cussions on longitudinal standardized data as a team,
practising individualized evidence-based medicine.
The essence of evidence-based practice is to use knowl-
edge gained through research to inform specific clinical
choices. Decision supports are more likely to be used if
information is available in the regular flow of the office
visit. Connecting the patient and the psychiatrist with the
evidence at the time that it is needed and in a form that
both can understand is therefore another critical element
of redesigning the office visit to facilitate shared decision
making.
49
Both patients and psychiatrists need timely access to
research findings. Patients can benefit from orienting
information about the illnesses and what is known about
options to minimize symptoms and maximize function.
Psychiatrists and patients together can benefit from
Clinical research
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whole fields of knowledge into research-supported paths
for care.
59,60 Psychiatrists also need direct access to
detailed information when it is too voluminous or com-
plex to remember. Currently, this includes decision sup-
port in the form of drug-drug interactions that appear as
safety warnings in electronic records. Soon, it will encom-
pass individualized medicine: historical, medical, physio-
logical, and genetic information that will summarize
patient-specific risk factors.
The needs of people with severe and persistent mental
illnesses do not vary radically from site to site. Therefore,
a transformational psychiatrist office visit process that
weaves together all the elements that are needed for effi-
cient evidence-based psychiatric practice could be
designed, tested, packaged, and implemented widely.
Doing so shifts the office visit process to one that is
specifically designed to meet the needs of people who
have an ongoing psychiatric illness or vulnerability using
principles that have been shown to be helpful in improv-
ing the care of people with other persistent health diffi-
culties.
61
Personalized mental health care 
and shared decision making
Creating a flow of care that makes sharing decisions nat-
ural and efficient will be even more important when we
have access to tests that will provide us with person-level
information that is relevant to mental health care deci-
sions. The current state of treatment selection in mental
health is characterized by multiple choices, with little evi-
dence to guide decisions to select initial or subsequent
treatments.
62,63 Genetic or molecular factors might help
inform treatment selection by identifying a priori people
likely to have side effects, such as treatment-emergent
suicidal ideation in response to antidepressants,
64 or
metabolic syndromes with antipsychotic treatment.
65
Genetic testing might also identify people needing par-
ticularly low or high doses of medications,
66 people more
likely to attain remissions,
67,68 or even people more likely
to respond to a certain medication mechanism of action.
69
Identification of individual genetic or molecular factors,
in the future, may help establish diagnoses in people with
subsyndromal symptoms or unclear diagnoses, as well as
further inform asymptomatic relatives of people with
mental illnesses in making reproductive decisions and
personal lifestyle choices.
70
At the same time, information of this type might also cre-
ate social and psychological risks and pessimism in regard
to the effectiveness of treatments.
71 Potential adverse con-
sequences could affect emotional well-being, family rela-
tionships, employment, and insurance.
72,73Thus, the poten-
tial of psychiatric genomics has fueled ongoing ethical
and legal debates.
74,75
The availability of such complex information needs to be
paired with a structured system of communicating the
benefits and the risks of testing to patients to allow its
effective incorporation into the process of shared med-
ical decision making. In other areas of medicine, studies
of communication of genetic information to patients have
identified the importance of education, risk communica-
tion, and emotional support.
76-78
Genetic information dramatically increases the com-
plexity of risk. In cancer genetics, Huiart et al
79 outlined
the difference between the individual risk of inheriting
or transmitting predisposing genes and the individual
risk of developing the disease. This is highly relevant for
mental health, as most neuropsychiatric disorders are
polygenic, and any single gene variation may have min-
imal impact on individual risk. Gene variations can have
additive effects on the expression of a phenotype,
80 or a
certain gene variation might be expressed only through
interaction with the environment.
81The ability of a test
to identify gene variation might be different from 
its ability to identify the phenotype of interest.
Furthermore, for example in cytochrome system testing,
identifying a certain phenotype, such as slow metabo-
lizers, may or may not have clinical utility, depending on
other factors, such as ethnicity or the medication choice
involved.
66
As in other areas of medicine, communicating the mean-
ings of uncertainty, risk, and statistics in mental health
conditions is difficult.
82 Patient education needs to include
not only information about choices but also information
to enhance statistical literacy. Several research findings
have helped this field. For example, using absolute risks
rather than relative risks and transforming probabilities
into natural frequencies displayed as pictograms facili-
tate communication and understanding.
83,84
Specialized genetic counselors have traditionally pro-
vided risk information in medical genetics. More
recently, decision aids focused on risk communication
and patient education have become prominent.
77,85 A
recent review of risk communication interventions found
that decision aids improved knowledge, but did not nec-
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77 Availability of decision aids
prior to the encounter with a clinician did, however,
increase time for discussion of personal risk rather than
education.
86
Individual counseling has been identified as an important
element of genetic communication to improve risk per-
ception and to address the psychological and social
effects of genetic testing on the patient and the fam-
ily.
71,77,87,88 Inaccurate perceptions of risk after communi-
cation were associated with the psychological health of
the individual.
79 One-on-one counseling was associated
with reduced decision conflict in general medicine,
89 but
research on counseling related to genetic risk in mental
health has not yet been done. Joint psychiatrist-genetic
counselor consultation and family–based approaches
have been proposed in mental health.
90
Psychiatrists, as well as other medical providers, score low
on scales of patient involvement in decision making,
91
perhaps in part because traditional genetic counseling
has been based on autonomous choice models.
92
Increased patient activation was described when men-
tal health patients’ own strategies for well-being and
recovery were identified and supported.
15 In general,
patients expect and prefer help with decision making in
studies of genetic information communication.
78,93
Shared decision making in mental health will need to
incorporate, in the future, effective communication
regarding genetic and molecular testing. Structured
assessments prior to the consultation will facilitate
expression of the patient’s goals and values, including
goals for genetic testing. Decision aids provided prior
to the consultation could increase patients’ knowledge
and individualize information. The encounter with a
provider should facilitate risk communication and deci-
sion making. 
Limitations
The barriers to shared decision making are legion.
94
Clinicians lack familiarity and training, sometimes dis-
agree with the concept, and often have concerns regard-
ing decisional capacity and legal responsibility. Patients
often lack the information, empowerment, motivation,
and self-efficacy needed to participate in shared decision
making. Mental health systems almost universally lack
the needed computer infrastructure. At a basic science
level, concerns involve communicating uncertainty and
risk, biases in many decision aids, and human biases in
decision making in general.
95,96 For example, mental
health patients, like others, are biased by optimism
regarding their own health, are confused by too many
choices, have difficulties understanding statistical risks,
and are influenced by biased information from industry.
These issues need to be clarified by further research and
addressed at many levels: basic decision-making science,
clinician training, structural implementation, electronic
infrastructure, patient empowerment, and so forth. 
Summary and conclusions
Implementing shared decision making in routine mental
health care offers considerable promise in terms of ethics,
quality, informed decisions, patient satisfaction, enhanced
ability for self-management, improved adherence, and
meaningful outcomes. Putting these potentialities into
everyday practice will be fraught with difficulties. Now is
the time to address these barriers through research on
shared decision making, as the information explosion and
personalized medicine will require new educational
structures, communication patterns, and decision-making
forms.  ❏
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La toma de decisiones compartidas en salud
mental: perspectivas para la medicina 
personalizada
Este artículo describe el modelo de la toma de deci-
siones compartidas, revisa su situación actual en el
campo de la salud mental y discute su potencial
impacto en la medicina personalizada. La toma de
decisiones compartidas traduce un proceso estruc-
turado que fomenta la participación total del
paciente y del proveedor. La investigación actual
muestra que la toma de decisiones compartidas
puede mejorar la participación de los pacientes
mentales y la calidad de las decisiones en términos
del conocimiento y los valores. Se debe estudiar el
impacto de la toma de decisiones compartidas en la
adherencia, el auto manejo de la enfermedad y las
consecuencias en la salud. La implementación de la
toma de decisiones compartidas en líneas genera-
les requerirá de una reingeniería del circuito de la
atención clínica en los ambientes de práctica coti-
diana y un mayor empleo de la tecnología de la
información. Se necesitarán cambios similares para
combinar datos genómicos y otros datos biológicos
con los valores y preferencias de los pacientes, y con
la experiencia de los clínicos. El futuro de la medi-
cina personalizada está claramente relacionado con
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receptividad cultural a estos cambios.   
Prise de décision partagée en santé 
mentale : en quête d’une médecine 
personnalisée
Cet article décrit le modèle de prise de décision par-
tagée, le resitue dans le cadre actuel de la santé
mentale et analyse son influence potentielle dans
la médecine personnalisée. La prise de décision par-
tagée est un processus structuré qui encourage la
participation entière du patient et du médecin. La
recherche actuelle montre que cette prise de déci-
sion peut favoriser la participation des patients psy-
chiatriques et la qualité des décisions en termes de
connaissances et de valeurs. Il faut en étudier l’in-
fluence sur l’adhésion au traitement, la prise  en
charge individuelle de la maladie par le patient et
l’évolution deson’état de santé. La mise en œuvre
étendue de cette prise de décision partagée néces-
sitera de réorganiser les soins cliniques dans le cadre
d’une pratique de routine et d’ utiliser de manière
plus importante les technologies de l’information.
Associer la génomique et les autres données biolo-
giques avec les préférences des patients et l’expé-
rience des médecins demandera également des
changements.  L’avenir de la médecine personnali-
sée dépend clairement de notre capacité à créer
l’infrastructure et la réceptivité culturelle à ces
changements.
10. Montori VM, Gafni A, Charles C. A shared treatment decision-making
approach between patients with chronic conditions and their clinicians: the
case of diabetes. Health Expect. 2006;9:25-36.
11. Wagner EH, Glasgow RE, Davis C, et al. Quality improvement in chronic
illness care: a collaborative approach. Jt Comm J Qual Improv. 2001;27:63-80.
12. Mueser KT, Corrigan PW, Hilton DW, et al. Illness management and
recovery: a review of the research. Psychiatr Serv. 2002;53:1272-1284.
13. Charles C, DeMaio S. Lay participation in health care decision making:
a conceptual framework. J Health Polit Policy Law. 1993;18:881-904.
14. Charles C, Gafni A, Whelan T. Shared decision-making in the medical
encounter: what does it mean? (or it takes at least two to tango). Soc Sci
Med. 1997;44:681-692.
15. Deegan PE, Drake RE. Shared decision making and medication man-
agement in the recovery process. Psychiatr Serv. 2006;57:1636-1639.
16. Schneider C. The Practice of Autonomy: Patients, Doctors, and Medical
Decisions. New York, NY: Oxford University Press; 1998.
17. King JS, Moulton BW. Rethinking informed consent: the case for
shared medical decision-making. Am J Law Med. 2006;32:429-501.
18. Adams JR, Drake RE, Wolford GL. Shared decision-making preferences
of people with severe mental illness. Psychiatr Serv. 2007;58:1219-1221.
19. Hamann J, Cohen R, Leucht S, Busch R, Kissling W. Do patients with
schizophrenia wish to be involved in decisions about their medical treat-
ment? Am J Psychiatry. 2005;162:2382-2384.
20. Noble LM, Douglas BV. What users and relatives want from mental
health services. Curr Opin Psychiatry. 2004;17:289-296.
21. O'Neal EL, Adams JR, McHugo GJ, Van Citters AD, Drake RE, Bartels SJ.
Preferences of older, middle-aged and younger adults with severe mental
illness for involvement in shared decision making in medical and psychiatric
settings. Am J Geriatr Psychiatry. 2008;16:826-833.
22. Mistler LA, Drake RE. Shared decision making in antipsychotic man-
agement. J Psychiatr Pract. 2008;14:333-344.
23. Deegan PE. The lived experience of using psychiatric medication in the
recovery process and a shared decision-making program to support it.
Psychiatr Rehabil J. 2007;31:62-69.
24. Hamann J, Mendel R, Cohen R, et al. Self-reported use of shared deci-
sion making among psychiatrists in the treatment of schizophrenia. Influence
of patient characteristics and decision topics. Psychiatr Serv. 2009;60:1107-1112.
25. Seale C, Chaplin R, Lelliott P, Quirk A. Sharing decisions in consultations
involving anti-psychotic medication: a qualitative study of psychiatrists'
experiences. Soc Sci Med. 2006;62:2861-2873.
26. Carpenter W, Gold JM, Lahti AC, et al. Decisional capacity for informed
consent in schizophrenia research. Arch Gen Psychiatry. 2000;57:533-538.
27. Grisso T, Applebaum PS. The MacArthur treatment competence study.
III. Abilities of patients to consent to psychiatric and medical treatments.
Law Human Behavior. 1995;19:149-174.
28. Stroup S, Appelbaum P, Swartz MS, et al. Decision-making capacity for
research participation among individuals in the CATIE schizophrenia trial.
Schizophr Res. 2005;80:1-8.
29. McGurk SR, Mueser KT. Strategies for coping with cognitive impair-
ments of clients in supported employment. Psychiatr Serv. 2006;57:1421-1429.
DCNS_43_4.qxd:DCNS#43  1/12/09  23:59  Page 461Clinical research
462
30. Swanson J, Swartz M, Ferron J, Elbogen E, Van Dorn R. Psychiatric
advance directives among public mental health consumers in five U.S. cities:
prevalence, demand, and correlates. J Am Acad Psychiatry Law. 2006;34:43-
57.
31. Bond GR, Salyers MP, Rollins AL, Rapp CA, Zipple AM. How evidence-
based practices contribute to community integration. Community Ment
Health J. 2004;40:569-588.
32. Corrigan PW. Recovery from schizophrenia and the role of evidence-
based psychosocial interventions. Expert Rev Neurother. 2006;6:993-1004.
33. Becker DR, Xie H, McHugo GJ, Halliday J, Martinez RA. What predicts
supported employment program outcomes? Community Ment Health J.
2006;42:303-313.
34. Bond GR. Supported employment: evidence for an evidence-based
practice. Psychiatr Rehabil J. 2004;27:345-359.
35. Mueser KT, Glynn SM, Liberman RP. Behavioral family management for
serious psychiatric illness. New Dir Ment Health Serv. 1994:37-50.
36. Mueser KT, Drake, R.E. Treatment of co-occurring substance use disor-
ders using shared decision making and electronic decision support systems.
In: Rudnick A, Roe D, eds. Serious Mental Illness (SMI): Person-centered
Approaches. Radcliff Press. In press.
37. Miller AL, Crismon Ml, Rush AJ, et al. The Texas Medication Algorithm
Project: Clinical results for schizophrenia. Schizophr Bull. 2004;30:627-647.
38. Salyers MP, Tsemberis S. ACT and recovery: integrating evidence-based
practice and recovery orientation on assertive community treatment teams.
Community Ment Health J. 2007;43:619-641.
39. Malm U, Ivarsson B, Allebeck P, Falloon I. Integrated care in schizo-
phrenia: a two-year randomized controlled study of two community-based
treatment programs. Acta Psychiatrica Scandinavica. 2003;107:415-423.
40. Van Korff M, Katon W, Rutter C, et al. Effect on disability outcomes of a
depression relapse prevention program. Psychosomatic Med. 2003;65:938-943.
41. Van Os J, Altamura AC, Bobes J, et al. Evaluation of the Two-Way
Communication Checklist as a clinical intervention. Results of a multina-
tional, randomised controlled trial. Br J Psychiatry. 2004;184:79-83
42. Hamann J, Langer B, Winkler V, et al. Shared decision making for in-
patients with schizophrenia. Acta Psychiatrica Scandinavica. 2006;114:265-273.
43. Priebe S, McCabe R, Bullenkamp J, Hansson L, Lauber C, Martinez-Leall
R. Structured patient-clinician communication and 1-year outcome in com-
munity mental healthcare. Br J Psychiatry. 2007;191:420-426.
44. Loh A, Simon D, Wills CE, Kriston L, Niebling W, Harter M. The effects
of a shared decision-making intervention in primary care of depression: a
cluster-randomized controlled trial. Patient Educ Couns. 2007;67:324-332.
45. Joosten EAG, de Jong CAJ, de Weert-van Oene GH, T S, van der Staak
CPF. Shared decision-making reduces drug use and psychiatric severity in
substance-dependent patients. Psychother Psychosom. 2009;78:245-253.
46. Woltmann EM. Development and investigation of a decision support
system to facilitate shared decision making in community mental health
[Dissertation]. Dartmouth Medical School; 2009.
47. Fraenkel L, McGraw S. What are the essential elements to enable
patient participation in medical decision making? J Gen Intern Med.
2007;22:614-619.
48. O'Connor AM, Stacey D, Entwistle V, et al. Decision aids for people fac-
ing health treatment or screening decisions. Cochrane Database Syst Rev.
2003:CD001431.
49. Batalden PB, Nelson EC, Mohr JJ, et al. Microsystems in health care:
Part 5. How leaders are leading. Jt Comm J Qual Saf. 2003;29:297-308.
50. Torrey WC, Green RL, Drake RE. Psychiatrists and psychiatric rehabili-
tation. J Psychiatr Pract. 2005;11:155-160.
51. Seidman J. The Arrival of 21st Century Health Care: Group Health
Cooperative Reengineers Its Delivery System Around Information Therapy
and Patient-Centered Informatics. Available at: http://www.ixcenter.org/pub-
lications/documents/e0067.pdf.
52. Batalden PB, Stoltz PK. A framework for the continual improvement
of health care: building and applying professional and improvement knowl-
edge to test changes in daily work. Jt Comm J Qual Improv. 1993;19:424-447;
discussion 48-52.
53. Deegan P, Rapp CA, Holter M, Riefer M. A program to support shared
decision making in an outpatient psychiatric medication clinic. Psychiatr Serv.
2008;59:603-605.
54. Drake RE, Teague GB, Gersing K. State mental health authorities and
informatics. Community Ment Health J. 2005;41:365-370.
55. Deegan PE, Rapp C, Holter M, Riefer M. Best practices: a program to
support shared decision making in an outpatient psychiatric medication
clinic. Psychiatr Serv. 2008;59:603-305.
56. Rimondini M, Del Piccolo L, Goss C, Mazzi M, Paccaloni M,
Zimmermann C. Communication skills in psychiatry residents - how do they
handle patient concerns? An application of sequence analysis to interviews
with simulated patients. Psychother Psychosom. 2006;75:161-169.
57. Chinman M, Young AS, Schell T, Hassell J, Mintz J. Computer-assisted
self-assessment in persons with severe mental illness. J Clin Psychiatry.
2004;65:1343-1351.
58. Wolford GL, Rosenberg SD, Rosenberg HJ, et al. A clinical trial com-
paring interviewer and computer-assisted assessment among clients with
severe mental illness. Psychiatr Serv. 2008;59:769-775.
59. Miller AL, Crismon ML, Rush AJ, et al. The Texas medication algorithm
project: clinical results for schizophrenia. Schizophr Bull. 2004;30:627-647.
60. Trivedi MH, Rush AJ, Crismon ML, et al. Clinical results for patients with
major depressive disorder in the Texas Medication Algorithm Project. Arch
Gen Psychiatry. 2004;61:669-680.
61. Wagner EH, Austin BT, Davis C, Hindmarsh M, Schaefer J, Bonomi A.
Improving chronic illness care: translating evidence into action. Health Aff
(Millwood). 2001;20:64-78.
62. Zisook S, Ganadjian K, Moutier C, Prather R, Rao S. Sequenced
Treatment Alternatives to Relieve Depression (STAR*D): lessons learned. J
Clin Psychiatry. 2008;69:1184-1185.
63. Lieberman JA, Stroup TS, McEvoy JP, et al. Effectiveness of antipsychotic
drugs in patients with chronic schizophrenia. N Engl J Med. 2005;353:1209-
1223.
64. Laje G, Paddock S, Manji H, et al. Genetic markers of suicidal ideation
emerging during citalopram treatment of major depression. Am J Psychiatry.
2007;164:1530-1538.
65. de Leon J. Pharmacogenomics: the promise of personalized medicine
for CNS disorders. Neuropsychopharmacology. 2009;34:159-172.
65. de Leon J. AmpliChip CYP450 test: personalized medicine has arrived
in psychiatry. Expert Rev Mol Diagn. 2006;6:277-286.
67. Laje G, McMahon FJ. The pharmacogenetics of major depression: past,
present, and future. Biol Psychiatry. 2007;62:1205-1207.
68. Lekman M, Paddock S, McMahon FJ. Pharmacogenetics of major
depression: insights from level 1 of the Sequenced Treatment Alternatives
to Relieve Depression (STAR*D) trial. Mol Diagn Ther. 2008;12:321-330.
69. Lin KM, Perlis RH, Wan YJ. Pharmacogenomic strategy for individual-
izing antidepressant therapy. Dialogues Clin Neurosci. 2008;10:401-408.
70. Roberts JS, Cupples LA, Relkin NR, Whitehouse PJ, Green RC. Genetic
risk assessment for adult children of people with Alzheimer's disease: the
Risk Evaluation and Education for Alzheimer's Disease (REVEAL) study. J
Geriatr Psychiatry Neurol. 2005;18:250-255.
71. Phelan JC, Yang LH, Cruz-Rojas R. Effects of attributing serious mental
illnesses to genetic causes on orientations to treatment. Psychiatr Serv.
2006;57:382-387.
72. Ruano G. Quo vadis personalized medicine? Personalized Medicine.
2004;1:1-7.
73. Hoop JG, Roberts LW, Green Hammond KA, Cox NJ. Psychiatrists' atti-
tudes regarding genetic testing and patient safeguards: a preliminary study.
Genet Test. 2008;12:245-252.
74. Dinwiddie SH, Hoop J, Gershon ES. Ethical issues in the use of genetic
information. Int Rev Psychiatry. 2004;16:320-328.
75. Hoop JG. Ethical considerations in psychiatric genetics. Harv Rev
Psychiatry. 2008;16:322-338.
76. Smets E, van Zwieten M, Michie S. Comparing genetic counseling with
non-genetic health care interactions: two of a kind? Patient Educ Couns.
2007;68:225-234.
77. Edwards A, Gray J, Clarke A, et al. Interventions to improve risk com-
munication in clinical genetics: systematic review. Patient Educ Couns.
2008;71:4-25.
78. Michie S, Allanson A, Armstrong D, Weinman J, Bobrow M, Marteau
TM. Objectives of genetic counselling: differing views of purchasers,
providers and users. J Public Health Med. 1998;20:404-408.
DCNS_43_4.qxd:DCNS#43  1/12/09  23:59  Page 462Shared decision making in mental health - Drake et al Dialogues in Clinical Neuroscience - Vol 11 . No. 4 . 2009
463
79. Huiart L, Eisinger F, Stoppa-Lyonnet D, et al. Effects of genetic consul-
tation on perception of a family risk of breast/ovarian cancer and determi-
nants of inaccurate perception after the consultation. J Clin Epidemiol.
2002;55:665-675.
80. Prathikanti S, Weinberger DR. Psychiatric genetics--the new era:
genetic research and some clinical implications. Br Med Bull. 2005;73-74:107-
122.
81. Caspi A, Sugden K, Moffitt TE, et al. Influence of life stress on depres-
sion: moderation by a polymorphism in the 5-HTT gene. Science.
2003;301:386-389.
82. Schwartz LM, Woloshin S, Welch HG. Using a drug facts box to com-
municate drug benefits and harms: two randomized trials. Ann Intern Med.
2009;150:516-527.
83. Gigerenzer G, Gaissmaier W, Kurz-Milcke E, Schwartz L, Woloshin S.
Helping doctors and patients make sense of health statistics. Psychological
Science in the Public Interest. 2007;8:53-96.
84. Hanoch Y, Pachur T. Nurses as information providers: facilitating under-
standing and communication of statistical information. Nurse Educ Today.
2004;24:236-243.
85. Lewis C, Mehta P, Kent A, Skirton H, Coviello D. An assessment of writ-
ten patient information provided at the genetic clinic and relating to
genetic testing in seven European countries. Eur J Hum Genet. 2007;15:1012-
1022.
86. Green MJ, Peterson SK, Baker MW, et al. Use of an educational com-
puter program before genetic counseling for breast cancer susceptibility:
effects on duration and content of counseling sessions. Genet Med.
2005;7:221-229.
87. Austin JC, Honer WG. The potential impact of genetic counseling for
mental illness. Clin Genet. 2005;67:134-142.
88. Kessler S. Psychological aspects of genetic counseling. XIV.
Nondirectiveness and counseling skills. Genet Test. 2001;5:187-191.
89. Green MJ, McInerney AM, Biesecker BB, Fost N. Education about
genetic testing for breast cancer susceptibility: patient preferences for a
computer program or genetic counselor. Am J Med Genet. 2001;103:24-31.
90. Austin JC, Honer WG. The genomic era and serious mental illness: a
potential application for psychiatric genetic counseling. Psychiatr Serv.
2007;58:254-261.
91. Goss C, Moretti F, Mazzi MA, Del Piccolo L, Rimondini M, Zimmermann
C. Involving patients in decisions during psychiatric consultations. Br J
Psychiatry. 2008;193:416-421.
92. Emery J. Is informed choice in genetic testing a different breed of
informed decision-making? A discussion paper. Health Expect. 2001;4:81-86.
93. Bernhardt BA, Geller G, Strauss M, et al. Toward a model informed con-
sent process for BRCA1 testing: a qualitative assessment of women's atti-
tudes. J Genet Couns. 1997;6:207-222.
94. Gravel K, Legare F, Graham ID. Barriers and facilitators to implement-
ing shared decision-making in clinical practice: a systematic review of health
professionals' perceptions. Implementation Science. 2006;1:2-33.
95. Chapman GB, Niedermayer LY. What counts as a decision? Predictors
of perceived decision making. Psychon Bull Rev. 2001;8:615-621.
96. Chapman GB, Weber BJ. Decision biases in intertemporal choice and
choice under uncertainty: testing a common account. Mem Cognit.
2006;34:589-602.
DCNS_43_4.qxd:DCNS#43  1/12/09  23:59  Page 463